[Bronchiolitis obliterans postallogeneic stem cell transplantation: what is new?]

Area of Science:

• Pulmonology
• Hematology
• Immunology

Context:

• Bronchiolitis obliterans (BO) is a severe complication following hematopoietic stem cell transplantation (HSCT).
• It presents as a respiratory manifestation of chronic graft-versus-host disease, sharing similarities with post-lung transplantation BO.
• Current standard therapies, including steroids and immunosuppressants, demonstrate limited efficacy and significant morbidity.

Purpose:

• To review emerging therapeutic strategies for bronchiolitis obliterans post-hematopoietic stem cell transplantation.
• To highlight recent advancements in understanding the pathophysiology of BO post-HSCT.
• To discuss the application of novel treatments in managing this condition.

Summary:

• This review focuses on novel therapeutic approaches for bronchiolitis obliterans (BO) after hematopoietic stem cell transplantation (HSCT).
• It examines treatments such as mTOR inhibitors, immunotherapy, extracorporeal photochemotherapy, and agents with anti-inflammatory effects like azithromycin, statins, and antileukotrienes.
• The discussion is informed by recent progress in understanding the underlying pathophysiology of BO post-HSCT.

Impact:

• Provides an overview of advanced treatment options for BO post-HSCT.
• Guides clinicians towards more effective management strategies for this challenging complication.
• Contributes to improved patient outcomes by exploring novel therapeutic avenues.